Literature DB >> 15238142

Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.

Pier Mannuccio Mannucci1, Cristina Capoferri, Maria Teresa Canciani.   

Abstract

ADAMTS-13, the metalloprotease that disposes physiologically of the most thrombogenic multimers of von Willebrand factor (VWF), tends to be low in plasma when VWF is high. We evaluated the behaviour of these two proteins in naturally occurring, experimental and clinical situations associated with VWF levels spanning from undetectable to supranormal. ADAMTS-13 was approximately 10% higher (and VWF 35% lower) in 65 healthy individuals of blood group O than in 65 individuals of groups A, B and AB. Thirty-three patients with type 3 von Willebrand disease (VWD) with undetectable plasma VWF had approximately 35% higher levels of ADAMTS-13 than a comparable group of healthy individuals with normal VWF. When VWF was raised to supranormal levels by desmopressin (DDAVP) in 10 healthy volunteers, ADAMTS-13 decreased by approximately 20%, with no change of the protease in three patients with severe VWD who had no post-DDAVP VWF rise. When VWF was raised from very low to normal levels by the infusion of VWF-containing plasma concentrates in four patients with type 3 VWD and one with type 1 VWD plasma, ADAMTS-13 decreased in parallel. These data show that throughout a large spectrum of plasma VWF levels there is a negative association between this protein and the activity of its major cleaving protease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238142     DOI: 10.1111/j.1365-2141.2004.05009.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

3.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

4.  Measurement of ADAMTS13.

Authors:  Han-Mou Tsai
Journal:  Int Rev Thromb       Date:  2006

Review 5.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

6.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

7.  Normal cleavage of von Willebrand factor by ADAMTS-13 in the absence of factor VIII in patients with severe hemophilia A.

Authors:  J Chen; D W Chung; J Le; M Ling; B A Konkle; J A López
Journal:  J Thromb Haemost       Date:  2013-09       Impact factor: 5.824

Review 8.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

9.  High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.

Authors:  Ehsan Valavi; Ali Ahmadzadeh; Parisa Amoori; Aidin Daneshgar
Journal:  Indian J Pediatr       Date:  2013-07-28       Impact factor: 1.967

10.  Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.

Authors:  Robert T Russell; Jenny K McDaniel; Wenjing Cao; Michelle Shroyer; Brant M Wagener; X Long Zheng; Jean-François Pittet
Journal:  Thromb Haemost       Date:  2018-04-04       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.